Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 16/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | KIT | P10721 | 4/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12408087 | 0.94 | CSF1R (0.72) | CSF1RCYP2C9KITCYP2C19CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL31157981 | 0.89 | CSF1R (0.75) | CSF1RCYP2C9KITCYP2C19CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL1859712 | 0.89 | CSF1R (0.67) | CSF1RCYP2C9KITCYP2C19 | |
| Trifluoroacetic Acid SCHEMBL1856490 | 0.88 | CSF1R (0.67) | CSF1RCYP2C9KITCYP2C19 | |
| Trifluoroacetic Acid SCHEMBL1862324 | 0.87 | CSF1R (0.67) | CSF1RCYP2C9KITCYP2C19 | |
| SCHEMBL12422506 | 0.86 | CSF1R (0.60) | CSF1RCYP2C9KITCYP2C19CYP3A4 | |
| SCHEMBL1868772 | 0.86 | CSF1R (0.60) | CSF1RCYP2C9KITCYP2C19CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL2943105 | 0.86 | CSF1R (0.69) | CSF1RCYP2C9KITCYP2C19CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL4983287 | 0.85 | CSF1R (0.68) | CSF1RCYP2C9KITCYP2C19CYP3A4 | |
| SCHEMBL1856332 | 0.85 | CSF1R (0.72) | CSF1RCYP2C9KITCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195960-A1 | INHIBITORS OF C-FMS KINASE | ILLIG CARL R | 2011-08-11 | — | — | US | disclosed |
| EP-2021335-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195960-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | CSF1R 59/4885CYP2C9 1815/4885KIT 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.